Lisinopril vs Losartan

Both lisinopril and losartan are effective first-line treatments for hypertension with well-established evidence bases. In head-to-head comparisons, both achieve similar blood pressure reductions of approximately 10-15 mmHg systolic and 6-10 mmHg diastolic at standard doses.

Lisinopril at 10-40 mg daily typically reduces blood pressure by 10-15/6-10 mmHg. Losartan at 50-100 mg daily achieves comparable reductions. The ALLHAT trial ^[1] (2002), one of the largest hypertension trials ever conducted, established ACE inhibitors (specifically lisinopril) as a first-line treatment option with outcomes comparable to diuretics.

For heart failure, both classes have demonstrated mortality benefits. The landmark CONSENSUS and SOLVD trials established ACE inhibitors as foundational heart failure therapy. The CHARM and ELITE II trials supported ARBs as effective alternatives. The ONTARGET trial ^[3] (2008) compared the ACE inhibitor ramipril with the ARB telmisartan and found similar cardiovascular outcomes, suggesting class-level equivalence.

For diabetic nephropathy ^[2], losartan has specific FDA approval based on the RENAAL trial ^[2], which demonstrated significant reductions in the progression of kidney disease. ACE inhibitors have similar renoprotective evidence. Current guidelines recommend either an ACE inhibitor or ARB (but not both together) for patients with diabetes and albuminuria.

Losartan has a unique property among ARBs: it has mild uricosuric effects, meaning it can slightly lower uric acid levels. This may be beneficial for patients with hypertension and gout.

The most significant side effect difference between these medication classes is the ACE inhibitor cough. Lisinopril and other ACE inhibitors cause a persistent dry cough in approximately 5-20% of patients, with higher rates in women and patients of Asian or African descent. This cough is caused by the accumulation of bradykinin, which ACE inhibitors prevent from being broken down.

Losartan and other ARBs do not cause this cough because they do not affect bradykinin metabolism. This is the primary reason ARBs were developed — as alternatives for patients who cannot tolerate ACE inhibitor cough.

Angioedema (swelling of the face, lips, tongue, or throat) is a rare but potentially life-threatening side effect of ACE inhibitors, occurring in approximately 0.1-0.7% of patients. ARBs carry a much lower risk of angioedema ^[4], though it is not zero. Patients who have experienced ACE inhibitor-induced angioedema ^[4] can usually safely take an ARB, though careful monitoring is recommended.

Both medications can cause hyperkalemia ^[4][5] (elevated potassium levels), particularly in patients with kidney disease or those taking potassium supplements. Both can cause dizziness due to blood pressure lowering. Both are absolutely contraindicated in pregnancy due to risk of fetal harm.

First-dose hypotension is possible with both medications but is generally mild. Neither medication causes the metabolic side effects (such as glucose elevation or lipid changes) seen with some other antihypertensive classes.

Both lisinopril and losartan are available as inexpensive generics. Lisinopril typically costs $4-$8 per month and is one of the most affordable prescription medications available. Losartan costs approximately $4-$12 per month.

Both are routinely included on $4 generic lists at major pharmacies and covered by essentially all insurance plans without prior authorization. Brand-name versions are rarely dispensed. Cost is generally not a deciding factor between these two medications.

For patients on combination therapy, lisinopril/hydrochlorothiazide (Zestoretic) and losartan/hydrochlorothiazide (Hyzaar) are both available as affordable generic combination tablets.

Both medications are taken orally once daily, making them equally convenient for adherence. Lisinopril is available in 2.5, 5, 10, 20, 30, and 40 mg tablets. Losartan comes in 25, 50, and 100 mg tablets.

Neither medication requires routine blood monitoring beyond periodic checks of kidney function (creatinine) and potassium levels, which are standard for any RAAS-blocking medication. Both can be taken with or without food at any time of day.

Losartan's shorter half-life means some patients may benefit from twice-daily dosing at lower doses, though once-daily dosing is standard. Lisinopril has a longer duration of action that reliably supports once-daily dosing.

The choice between lisinopril and losartan often comes down to tolerability. If you have never taken either medication, lisinopril is often tried first because it is slightly less expensive and has the longest clinical track record. However, if you develop a persistent cough — which affects up to 20% of ACE inhibitor users — switching to losartan typically resolves this issue while maintaining blood pressure control.

Losartan may be preferred as a first choice for patients with a history of ACE inhibitor cough, those of Asian or African descent (who have higher cough rates), patients with gout (due to losartan's uricosuric effect), or those who have experienced angioedema with ACE inhibitors.

For patients with diabetic kidney disease, both classes are appropriate. Losartan has specific trial evidence (RENAAL) for nephroprotection. For heart failure with reduced ejection fraction, ACE inhibitors remain the traditional first-line RAAS inhibitor, with ARBs reserved for those who cannot tolerate ACE inhibitors.

Both medications are contraindicated in pregnancy and should not be combined with each other. Discuss your medical history, other medications, and preferences with your healthcare provider to determine the best choice for you.